Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL563043 | 0.98 | GPR84 (0.97) | GPR84KMT2A | |
| SCHEMBL8160462 | 0.82 | GPR84 (0.70) | GPR84KMT2A | |
| SCHEMBL22547495 | 0.80 | GPR84 (0.67) | GPR84KMT2A | |
| SCHEMBL1702031 | 0.77 | GPR84 (0.96) | GPR84KMT2A | |
| SCHEMBL15752987 | 0.76 | KMT2A (0.97) | GPR84KMT2A | |
| SCHEMBL6996841 | 0.76 | KMT2A (0.97) | GPR84KMT2A | |
| SCHEMBL29948466 | 0.76 | KMT2A (0.97) | GPR84KMT2A | |
| SCHEMBL11739128 | 0.76 | KMT2A (0.97) | GPR84KMT2A | |
| SCHEMBL11736351 | 0.76 | KMT2A (0.97) | GPR84KMT2A | |
| SCHEMBL12867824 | 0.76 | GPR84 (0.72) | GPR84KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217911-A1 | A hydroxycarboxylic acid for the treatment of cancer | Universität Zürich (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240217911-A1 | A hydroxycarboxylic acid for the treatment of cancer | Universität Zürich (CH) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217911-A1 | A hydroxycarboxylic acid for the treatment of cancer | HCAR2, HCAR1, HCAR3 | GPR84 967/4885KMT2A 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.